



## Hepatocellular Carcinoma Pathogenesis and Therapy

Guest Editor:

### Dr. Junyan Tao

Pharmacology and Chemical  
Biology, University of Pittsburgh  
School of Medicine, Pittsburgh,  
PA 15261, USA

Deadline for manuscript  
submissions:

**closed (31 October 2025)**

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, ranked among the top six causes of cancer-related deaths worldwide. Over the past three decades, significant advancements have been made in unresectable advanced HCC treatment, starting with the FDA's approval of sorafenib as the first-line therapy drug. Since then, several other targeted therapy drugs have been approved as second-line treatments, and immune checkpoint inhibitors have gained prominence in clinical applications. Despite these advancements, there remains a substantial gap between pathological diagnosis, molecular characterization, optimized therapy strategies, and treatment outcomes.

This Special Issue aims to provide a comprehensive platform for the latest research and advancements in the understanding, diagnosis, and treatment of HCC.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)